Marija Brankovic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Marija Brankovic has a total of 115 co-authors. Here are the top co-authors by number of shared publications:
- Ana Marjanovic
Neurology Clinic University Clinical Center of Serbia Belgrade Serbia
11 shared publications - Milena Jankovic
Neurology Clinic, University Clinical Center of Serbia, 11000 Belgrade, Serbia
9 shared publications - Ivana Novakovic
Faculty of Medicine, University of Belgrade, Belgrade, Serbia
5 shared publications - Elka Stefanova
Faculty of Medicine, University of Belgrade, Belgrade, Serbia
4 shared publications - Marina Svetel
Neurology Clinic, University Clinical Center of Serbia, Belgrade, Serbia
4 shared publications - Vladimir Kostic
Neurology Clinic, University Clinical Center of Serbia, Belgrade, Serbia + Faculty of Medicine, University of Belgrade, Belgrade, Serbia
4 shared publications
Latest Publications
- 18 April 2026
- Published by University Library in Kragujevac in Preventive Paediatrics
- p. 009-013
KLINIČKI PRISTUP OBOLELIMA OD SKELETNIH DISPLAZIJA NAMENJEN PEDIJATRIMA
Uvod: Skeletne displazije obuhvataju heterogenu grupu oboljenja povezanih sa abnormalnostima skeletnog sistema. Većina skeletnih displazija je genetički determinisana. Sveobuhvatna klasifikacija skeletnih displazija podleže periodičnoj reviziji. Fenotipska prezentacija skeletnih displazija je vrlo varijabilna u zavisnosti od uključenih gena i mehanizama ispoljavanja njihove disfunkcije. Postavljanje dijagnoze je često izazovno jer mnoge skeletne displazije mogu imati sličan ili preklapajući fenotip. Cilj rada je definisanje praktičnih smernica u kliničkom radu sa decom obolelom od skeletne displazije. Želimo da pedijatre upoznamo sa fiziologijom razvoja skeleta i klasifikacijom skleletnih displazija, nakon čega sledi praktičan pristup u dijagnostici, lečenju i praćenju dece sa skeletnim displazijama. Metode rada: Ovo je pregledni rad za čiju su izradu korišćeni podaci dobijeni pretragom literature i rezultati naše retrospektivne kohortne studije koja je uključila 168 pacijenata sa sumnjom na skeletnu displaziju. Rezultati: Postavljanje dijagnoze skeletne displazije zahteva detaljnu kliničku, često radiološku, a nekada i laboratorijsku procenu. Genetičko testiranje bazirano na sekvenciranju naredne generacije odnosno genotipizacija predstavlja potvrdni alat za postavljanje precizne dijagnoze u mnogim slučajevima. Mnoge skeletne displazije zahtevaju precizan tretman kroz multidisciplinarni pristup i procenu povezanih komplikacija. Uloga pedijatara, na svim nivoima zdravstvene zaštite, je važna od prepoznavanja sumnje na postojanje skeletne displazije preko upućivanja na odgovarajuću dijagnostiku do praćenja ove dece uz prepoznavanje njihovih specifičnih potreba. Krajnji cilj je obezbeđivanje što boljeg kvaliteta života obolelima. Zaključak: Praktične smernice namenjene pedijatrima koji se u svom radu susreću sa decom obolelom od skeletnih displazija mogu umnogome olakšati njihov rad kroz prilagođen pristup ovim pacijentima.
- 18 April 2026
- Published by University Library in Kragujevac in Preventive Paediatrics
- p. 009-013
KLINIČKI PRISTUP OBOLELIMA OD SKELETNIH DISPLAZIJA NAMENJEN PEDIJATRIMA
Uvod: Skeletne displazije obuhvataju heterogenu grupu oboljenja povezanih sa abnormalnostima skeletnog sistema. Većina skeletnih displazija je genetički determinisana. Sveobuhvatna klasifikacija skeletnih displazija podleže periodičnoj reviziji. Fenotipska prezentacija skeletnih displazija je vrlo varijabilna u zavisnosti od uključenih gena i mehanizama ispoljavanja njihove disfunkcije. Postavljanje dijagnoze je često izazovno jer mnoge skeletne displazije mogu imati sličan ili preklapajući fenotip. Cilj rada je definisanje praktičnih smernica u kliničkom radu sa decom obolelom od skeletne displazije. Želimo da pedijatre upoznamo sa fiziologijom razvoja skeleta i klasifikacijom skleletnih displazija, nakon čega sledi praktičan pristup u dijagnostici, lečenju i praćenju dece sa skeletnim displazijama. Metode rada: Ovo je pregledni rad za čiju su izradu korišćeni podaci dobijeni pretragom literature i rezultati naše retrospektivne kohortne studije koja je uključila 168 pacijenata sa sumnjom na skeletnu displaziju. Rezultati: Postavljanje dijagnoze skeletne displazije zahteva detaljnu kliničku, često radiološku, a nekada i laboratorijsku procenu. Genetičko testiranje bazirano na sekvenciranju naredne generacije odnosno genotipizacija predstavlja potvrdni alat za postavljanje precizne dijagnoze u mnogim slučajevima. Mnoge skeletne displazije zahtevaju precizan tretman kroz multidisciplinarni pristup i procenu povezanih komplikacija. Uloga pedijatara, na svim nivoima zdravstvene zaštite, je važna od prepoznavanja sumnje na postojanje skeletne displazije preko upućivanja na odgovarajuću dijagnostiku do praćenja ove dece uz prepoznavanje njihovih specifičnih potreba. Krajnji cilj je obezbeđivanje što boljeg kvaliteta života obolelima. Zaključak: Praktične smernice namenjene pedijatrima koji se u svom radu susreću sa decom obolelom od skeletnih displazija mogu umnogome olakšati njihov rad kroz prilagođen pristup ovim pacijentima.
- Open Access
Enrichment of Rare Variants in Nuclear-Encoded Mitochondrial Metabolism Genes in Patients with Early-Onset or Familial Parkinson’s Disease
Introduction: Parkinson’s disease (PD) is a prevalent neurodegenerative disorder, with several proposed pathogenic mechanisms. Given the established role of mitochondrial dysfunction in PD, this study seeks to investigate the enrichment of rare genetic variants tied to mitochondrial metabolism in cases of early-onset and familial PD. Methods: We performed a retrospective analysis on 248 early-onset and familial PD patients and 1622 control individuals. We assessed both pathway-level and gene-level burden of germline rare variants detected using exome sequencing in 467 nuclear genes related to mitochondrial metabolism. Results: Gene-set mutation burden analysis indicated an increased burden in genes associated with mtDNA maintenance. In addition, gene-level analysis identified a possible association between PD and rare variant burden in 14 mitochondrial metabolism-related genes under dominant or recessive inheritance models. Conclusions: Our findings support a potential contribution of rare germline variants affecting mitochondrial metabolism to the susceptibility in early-onset and familial PD.
Open AccessEnrichment of Rare Variants in Nuclear-Encoded Mitochondrial Metabolism Genes in Patients with Early-Onset or Familial Parkinson’s Disease
Introduction: Parkinson’s disease (PD) is a prevalent neurodegenerative disorder, with several proposed pathogenic mechanisms. Given the established role of mitochondrial dysfunction in PD, this study seeks to investigate the enrichment of rare genetic variants tied to mitochondrial metabolism in cases of early-onset and familial PD. Methods: We performed a retrospective analysis on 248 early-onset and familial PD patients and 1622 control individuals. We assessed both pathway-level and gene-level burden of germline rare variants detected using exome sequencing in 467 nuclear genes related to mitochondrial metabolism. Results: Gene-set mutation burden analysis indicated an increased burden in genes associated with mtDNA maintenance. In addition, gene-level analysis identified a possible association between PD and rare variant burden in 14 mitochondrial metabolism-related genes under dominant or recessive inheritance models. Conclusions: Our findings support a potential contribution of rare germline variants affecting mitochondrial metabolism to the susceptibility in early-onset and familial PD.
- Open Access
- 11 December 2025
- Published by Ubiquity Press, Ltd. in Tremor and Other Hyperkinetic Movements
- Vol. 15 (1) , 62
Chorea in Hereditary Leukodystrophies – Overview of Two Cases
Background: Leukodystrophies are inherited heterogeneous diseases that are predominantly characterized by degenerative changes in the white matter of the central nervous system. These disorders begin both in childhood and in adulthood and have a complex phenotype that includes involuntary movements specifically chorea. Methods: This paper describes two female patients for whom generalized chorea was the primary clinical manifestation of leukodystrophy. Literature search was done through PubMed database with aim to included articles that described case reports of patients (both adult and childhood-onset) with leukodystrophy presenting with chorea in patients with metachromatic leukodystrophy (MLD) or L-2-hydroxiglutaric aciduria (L2HGA). Results: The first case presents MLD with adult-onset chorea combined with cognitive-behavioral changes mimicking Huntington’s disease, while the second case is caused by L2HGA and the diagnosis had been established in the adulthood. The search resulted in 163 articles, but only one in the end described phenotype suggestive of dyskinetic movement disorder. Discussion: Leukodystrophies, though primarily white matter disorders, can present with involuntary movements. Our cases with MLD and L2HGA highlight adult patients with chorea as a key manifestations, so metabolic and genetic testing is crucial in unexplained chorea. Highlights Leukodystrophies cause white matter degeneration and involuntary movements. We present two cases: one with MLD mimicking Huntington’s disease and one with L2HGA diagnosed in the adulthood. These clinical manifestations have not yet been precisely reported in the literature. This manuscript present rare adult-onset chorea in leukodystrophies and expands phenotypic diversity.
- 11 December 2025
- Published by Ubiquity Press, Ltd. in Tremor and Other Hyperkinetic Movements
- Vol. 15 (1) , 62
Open AccessChorea in Hereditary Leukodystrophies – Overview of Two Cases
Background: Leukodystrophies are inherited heterogeneous diseases that are predominantly characterized by degenerative changes in the white matter of the central nervous system. These disorders begin both in childhood and in adulthood and have a complex phenotype that includes involuntary movements specifically chorea. Methods: This paper describes two female patients for whom generalized chorea was the primary clinical manifestation of leukodystrophy. Literature search was done through PubMed database with aim to included articles that described case reports of patients (both adult and childhood-onset) with leukodystrophy presenting with chorea in patients with metachromatic leukodystrophy (MLD) or L-2-hydroxiglutaric aciduria (L2HGA). Results: The first case presents MLD with adult-onset chorea combined with cognitive-behavioral changes mimicking Huntington’s disease, while the second case is caused by L2HGA and the diagnosis had been established in the adulthood. The search resulted in 163 articles, but only one in the end described phenotype suggestive of dyskinetic movement disorder. Discussion: Leukodystrophies, though primarily white matter disorders, can present with involuntary movements. Our cases with MLD and L2HGA highlight adult patients with chorea as a key manifestations, so metabolic and genetic testing is crucial in unexplained chorea. Highlights Leukodystrophies cause white matter degeneration and involuntary movements. We present two cases: one with MLD mimicking Huntington’s disease and one with L2HGA diagnosed in the adulthood. These clinical manifestations have not yet been precisely reported in the literature. This manuscript present rare adult-onset chorea in leukodystrophies and expands phenotypic diversity.
- Open Access
- 18 July 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (14) , 5119
Genetic Susceptibility to Glomerulonephritis in Children: Analysis of Structural Kidney Genes and Immune System Genes
Background/Objectives: Glomerulonephritis (GNs) is a heterogeneous group of inflammatory kidney diseases. Novel genetic methods have revealed some disease-causing and susceptibility genes underlying primary and secondary GNs. We aimed to investigate the presence of the single nucleotide polymorphisms (SNPs) rs12917707, found in the UMOD gene, and rs17319721, found in the SHROOM3 gene, as well as different polymorphisms in immune system genes in a group of children with GN. Method: The study included 71 children with GN (40 with primary and 31 with secondary GN) and 119 healthy children (HC). SNPs of the UMOD (rs12917707), SHROOM3 (rs17319721), IL10 (rs1800871 and rs3024505), IL6 (rs1800795), IL12B (rs3212227), IL23R (rs11209026 and rs1800896), and TNF (rs361525 and rs1800629) genes were genotyped. Results: The median age of the patients was 8 years at the onset of GN and 14 years at sampling. Allele A for rs1800629 in the TNF gene was more common in patients with GN in comparison to HCs (p = 0.009), followed by the difference in genotype distributions (p = 0.021), where AA and GA genotypes were more prevalent in patients. We found a statistically significant difference in haplotype distributions between patients and HCs for TNF, with GN patients having the GGAG haplotype more frequently and HCs having GGGG (p < 0.05). No correlation between the investigated SNPs and patient clinical characteristics (disease onset, primary or secondary GN, severity of disease, occurrence of remission, and presence of hypertension) was observed. Conclusions: An association between the TNF gene and different types of GN was noticed in children with GN. This may help us to understand the pathogenesis of these disorders and develop new treatments to cover the unmet needs of children with GN.
- 18 July 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (14) , 5119
Open AccessGenetic Susceptibility to Glomerulonephritis in Children: Analysis of Structural Kidney Genes and Immune System Genes
Background/Objectives: Glomerulonephritis (GNs) is a heterogeneous group of inflammatory kidney diseases. Novel genetic methods have revealed some disease-causing and susceptibility genes underlying primary and secondary GNs. We aimed to investigate the presence of the single nucleotide polymorphisms (SNPs) rs12917707, found in the UMOD gene, and rs17319721, found in the SHROOM3 gene, as well as different polymorphisms in immune system genes in a group of children with GN. Method: The study included 71 children with GN (40 with primary and 31 with secondary GN) and 119 healthy children (HC). SNPs of the UMOD (rs12917707), SHROOM3 (rs17319721), IL10 (rs1800871 and rs3024505), IL6 (rs1800795), IL12B (rs3212227), IL23R (rs11209026 and rs1800896), and TNF (rs361525 and rs1800629) genes were genotyped. Results: The median age of the patients was 8 years at the onset of GN and 14 years at sampling. Allele A for rs1800629 in the TNF gene was more common in patients with GN in comparison to HCs (p = 0.009), followed by the difference in genotype distributions (p = 0.021), where AA and GA genotypes were more prevalent in patients. We found a statistically significant difference in haplotype distributions between patients and HCs for TNF, with GN patients having the GGAG haplotype more frequently and HCs having GGGG (p < 0.05). No correlation between the investigated SNPs and patient clinical characteristics (disease onset, primary or secondary GN, severity of disease, occurrence of remission, and presence of hypertension) was observed. Conclusions: An association between the TNF gene and different types of GN was noticed in children with GN. This may help us to understand the pathogenesis of these disorders and develop new treatments to cover the unmet needs of children with GN.
- 15 November 2024
- Published by Wiley in Annals of Human Genetics
- Vol. 89 (2-3) , 67-76
Secondary findings in 443 exome sequencing data
Exome sequencing (ES) may identify and report secondary findings that are unrelated to the primary disease for which the patient underwent genetic testing, but are of potential value in patient care. In this study, we evaluated 81 American College of Medical Genetics (ACMG) medically actionable genes in 443 patients with various neurological disorders. The variants identified were classified and reported following the 2015 ACMG Standards and Guidelines for the interpretation of sequence variants and the ACMG recommendations for reporting secondary findings (v3.2). We detected a total of 17 variants in 17 patients across 9 different genes as secondary findings. Seven heterozygous variants were found in BRCA1, MSH2 , and PALB2 which are part of the cancer phenotype category. Nine heterozygous variants were found in MYH7 , TTN , LDLR , DSC2 , and DSP which are part of the cardiovascular phenotype category. Finally, one heterozygous variant was found in TTR which is part of the miscellaneous phenotype category. Thirteen of above mentioned variants were classified as known pathogenic and four as expected pathogenic. The information collected in our study may lead to the prevention of severe morbidity and mortality and provides additional insight into the genetic background of the Serbian population.
- 15 November 2024
- Published by Wiley in Annals of Human Genetics
- Vol. 89 (2-3) , 67-76
Secondary findings in 443 exome sequencing data
Exome sequencing (ES) may identify and report secondary findings that are unrelated to the primary disease for which the patient underwent genetic testing, but are of potential value in patient care. In this study, we evaluated 81 American College of Medical Genetics (ACMG) medically actionable genes in 443 patients with various neurological disorders. The variants identified were classified and reported following the 2015 ACMG Standards and Guidelines for the interpretation of sequence variants and the ACMG recommendations for reporting secondary findings (v3.2). We detected a total of 17 variants in 17 patients across 9 different genes as secondary findings. Seven heterozygous variants were found in BRCA1, MSH2 , and PALB2 which are part of the cancer phenotype category. Nine heterozygous variants were found in MYH7 , TTN , LDLR , DSC2 , and DSP which are part of the cardiovascular phenotype category. Finally, one heterozygous variant was found in TTR which is part of the miscellaneous phenotype category. Thirteen of above mentioned variants were classified as known pathogenic and four as expected pathogenic. The information collected in our study may lead to the prevention of severe morbidity and mortality and provides additional insight into the genetic background of the Serbian population.
- 19 March 2024
- Published by Springer Nature in neurogenetics
- Vol. 25 (3) , 165-177
Whole exome sequencing in Serbian patients with hereditary spastic paraplegia
Hereditary spastic paraplegia (HSP) is a group of neurodegenerative diseases with a high genetic and clinical heterogeneity. Numerous HSP patients remain genetically undiagnosed despite screening for known genetic causes of HSP. Therefore, identification of novel variants and genes is needed. Our previous study analyzed 74 adult Serbian HSP patients from 65 families using panel of the 13 most common HSP genes in combination with a copy number variation analysis. Conclusive genetic findings were established in 23 patients from 19 families (29%). In the present study, nine patients from nine families previously negative on the HSP gene panel were selected for the whole exome sequencing (WES). Further, 44 newly diagnosed adult HSP patients from 44 families were sent to WES directly, since many studies showed WES may be used as the first step in HSP diagnosis. WES analysis of cohort 1 revealed a likely genetic cause in five (56%) of nine HSP families, including variants in the ETHE1, ZFYVE26, RNF170, CAPN1, and WASHC5 genes. In cohort 2, possible causative variants were found in seven (16%) of 44 patients (later updated to 27% when other diagnosis were excluded), comprising six different genes: SPAST, SPG11, WASCH5, KIF1A, KIF5A, and ABCD1. These results expand the genetic spectrum of HSP patients in Serbia and the region with implications for molecular genetic diagnosis and future causative therapies. Wide HSP panel can be the first step in diagnosis, alongside with the copy number variation (CNV) analysis, while WES should be performed after.
- 19 March 2024
- Published by Springer Nature in neurogenetics
- Vol. 25 (3) , 165-177
Whole exome sequencing in Serbian patients with hereditary spastic paraplegia
Hereditary spastic paraplegia (HSP) is a group of neurodegenerative diseases with a high genetic and clinical heterogeneity. Numerous HSP patients remain genetically undiagnosed despite screening for known genetic causes of HSP. Therefore, identification of novel variants and genes is needed. Our previous study analyzed 74 adult Serbian HSP patients from 65 families using panel of the 13 most common HSP genes in combination with a copy number variation analysis. Conclusive genetic findings were established in 23 patients from 19 families (29%). In the present study, nine patients from nine families previously negative on the HSP gene panel were selected for the whole exome sequencing (WES). Further, 44 newly diagnosed adult HSP patients from 44 families were sent to WES directly, since many studies showed WES may be used as the first step in HSP diagnosis. WES analysis of cohort 1 revealed a likely genetic cause in five (56%) of nine HSP families, including variants in the ETHE1, ZFYVE26, RNF170, CAPN1, and WASHC5 genes. In cohort 2, possible causative variants were found in seven (16%) of 44 patients (later updated to 27% when other diagnosis were excluded), comprising six different genes: SPAST, SPG11, WASCH5, KIF1A, KIF5A, and ABCD1. These results expand the genetic spectrum of HSP patients in Serbia and the region with implications for molecular genetic diagnosis and future causative therapies. Wide HSP panel can be the first step in diagnosis, alongside with the copy number variation (CNV) analysis, while WES should be performed after.
- Open Access
- 30 September 2023
- Published by The Korean Movement Disorder Society in Journal of Movement Disorders
- Vol. 16 (3) , 333-335
Clinical and Genetic Features of Huntington’s Disease Patients From Republic of Serbia: A Single-Center Experience
- 30 September 2023
- Published by The Korean Movement Disorder Society in Journal of Movement Disorders
- Vol. 16 (3) , 333-335
Open AccessClinical and Genetic Features of Huntington’s Disease Patients From Republic of Serbia: A Single-Center Experience
- Open Access
- 1 January 2023
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Medicinska istrazivanja
- Vol. 56 (4) , 67-74
The association of R47H variant in the TREM2 gene and genetic susceptibility to Alzheimer's disease in Serbian population
Introduction: Alzheimer's disease (AD) is a chronic neurodegenerative disease, which is clinically manifested by the development of dementia. Studies of genetic susceptibility to AD indicate a whole range of genes and their variants that can potentially influence an individual's susceptibility to develope the disease. AD17 represents a form of Alzheimer's disease associated with mutation(s) in the TREM2 gene, encoding triggering receptor expressed on myeloid cells 2. The aim of this study was to determine the frequency of R47H variant of the TREM2 gene in the population of AD patients, to compare the frequency of the variant in the population of AD patients and the control group, and to determine a possible association of a certain genotype with susceptibility to AD. Material and Methods: The study included 168 consecutive patients with AD and 190 healthy controls. The clinical inerview, neurologic examination, and neuropsychological set of cognitive assessment were performed by neurologists and neuropsychologists in expertise with neurodegenerative deseases. Genotyping of rs75932628, R47H polymorphism of the TREM2 gene was performed using Real-time Polymerase Chain Reaction and TaqMan® SNP genotyping assay (Applied Biosystem by Thermo Fisher Scientific, USA) according to the manufacturer's recommendations. Results: In the group of AD patients the frequency of C allele was 98.8%, while the T allele was present in 1.2% of patients. The frequency of the T allele was statistically significantly higher among the AD population than among the control group (p<0.05). The frequency of homozygotes without mutation (CC genotype) was 97.62%, while the frequency of heterozygotes for the mutation (CT genotype) was 2.38% among patients with AD, and the frequency of homozygotes without mutation (CC genotype) was 100% among healthy controls. Conclusion: Our study indicated a possible association of the heterozygous form of the R47H variant of TREM2 gene with the susceptibility for the deve-lopement of AD in Serbian population.
- 1 January 2023
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Medicinska istrazivanja
- Vol. 56 (4) , 67-74
Open AccessThe association of R47H variant in the TREM2 gene and genetic susceptibility to Alzheimer's disease in Serbian population
Introduction: Alzheimer's disease (AD) is a chronic neurodegenerative disease, which is clinically manifested by the development of dementia. Studies of genetic susceptibility to AD indicate a whole range of genes and their variants that can potentially influence an individual's susceptibility to develope the disease. AD17 represents a form of Alzheimer's disease associated with mutation(s) in the TREM2 gene, encoding triggering receptor expressed on myeloid cells 2. The aim of this study was to determine the frequency of R47H variant of the TREM2 gene in the population of AD patients, to compare the frequency of the variant in the population of AD patients and the control group, and to determine a possible association of a certain genotype with susceptibility to AD. Material and Methods: The study included 168 consecutive patients with AD and 190 healthy controls. The clinical inerview, neurologic examination, and neuropsychological set of cognitive assessment were performed by neurologists and neuropsychologists in expertise with neurodegenerative deseases. Genotyping of rs75932628, R47H polymorphism of the TREM2 gene was performed using Real-time Polymerase Chain Reaction and TaqMan® SNP genotyping assay (Applied Biosystem by Thermo Fisher Scientific, USA) according to the manufacturer's recommendations. Results: In the group of AD patients the frequency of C allele was 98.8%, while the T allele was present in 1.2% of patients. The frequency of the T allele was statistically significantly higher among the AD population than among the control group (p<0.05). The frequency of homozygotes without mutation (CC genotype) was 97.62%, while the frequency of heterozygotes for the mutation (CT genotype) was 2.38% among patients with AD, and the frequency of homozygotes without mutation (CC genotype) was 100% among healthy controls. Conclusion: Our study indicated a possible association of the heterozygous form of the R47H variant of TREM2 gene with the susceptibility for the deve-lopement of AD in Serbian population.
- Open Access
- 1 January 2022
- Published by National Library of Serbia in Genetika
- Vol. 54 (3) , 1351-1364
Analysis of “clinical exome” panel in Serbian patients with cognitive disorders
As life span rises, dementia has become a growing public health issue. According to current estimates, almost 50 million people worldwide have dementia, and the number is expected to grow. Next generation sequencing (NGS) methods have helped significantly with identifying causative gene variants related to various cognitive disorders. Our study aimed to analyze the genetic basis of cognitive disorders using NGS clinical exome panel. The study included a total number of 15 unrelated cases diagnosed with cognitive disorders, all negative after standard targeted genetic testing was performed (available at Neurology Clinic, UCCS, Belgrade, Serbia). Preference was given to familial cases with early presentation or complex phenotype. Sequencing of a clinical exome (CE) panel for 4813 genes with known associated clinical phenotypes was performed using TruSight One sequencing panel on an Illumina MiSeq NGS platform according to the manufacturer?s instructions (Illumina, San Diego, CA, USA). Variants were analyzed with Illumina Variant Studio v3 software provided by Illumina as well as a previously developed pipeline. Variants analysis and interpretation were based on phenotype gene target approach, literature and databases search, allele frequency, and pathogenicity prediction by in silico software. All causative variants were confirmed by Sanger sequencing. Whenever possible, additional family members were studied for segregation analysis. CE panel analysis revealed a likely genetic cause in four patients. We have detected two missense heterozygous pathogenic variants in the PSEN1 gene in one patient each and homozygous nonsense pathogenic variant in the OPTN gene in two more patients. Detected pathogenic variants are in line with the clinical phenotype of our patients. In the rest of the 11 cases, genetic diagnosis remains unclear. The results of our study emphasize the significance of CE panel analysis in establishing a diagnosis for patients with dementia. Furthermore, give us insight into the complexity of the genetic background of this group of disorders.
- 1 January 2022
- Published by National Library of Serbia in Genetika
- Vol. 54 (3) , 1351-1364
Open AccessAnalysis of “clinical exome” panel in Serbian patients with cognitive disorders
As life span rises, dementia has become a growing public health issue. According to current estimates, almost 50 million people worldwide have dementia, and the number is expected to grow. Next generation sequencing (NGS) methods have helped significantly with identifying causative gene variants related to various cognitive disorders. Our study aimed to analyze the genetic basis of cognitive disorders using NGS clinical exome panel. The study included a total number of 15 unrelated cases diagnosed with cognitive disorders, all negative after standard targeted genetic testing was performed (available at Neurology Clinic, UCCS, Belgrade, Serbia). Preference was given to familial cases with early presentation or complex phenotype. Sequencing of a clinical exome (CE) panel for 4813 genes with known associated clinical phenotypes was performed using TruSight One sequencing panel on an Illumina MiSeq NGS platform according to the manufacturer?s instructions (Illumina, San Diego, CA, USA). Variants were analyzed with Illumina Variant Studio v3 software provided by Illumina as well as a previously developed pipeline. Variants analysis and interpretation were based on phenotype gene target approach, literature and databases search, allele frequency, and pathogenicity prediction by in silico software. All causative variants were confirmed by Sanger sequencing. Whenever possible, additional family members were studied for segregation analysis. CE panel analysis revealed a likely genetic cause in four patients. We have detected two missense heterozygous pathogenic variants in the PSEN1 gene in one patient each and homozygous nonsense pathogenic variant in the OPTN gene in two more patients. Detected pathogenic variants are in line with the clinical phenotype of our patients. In the rest of the 11 cases, genetic diagnosis remains unclear. The results of our study emphasize the significance of CE panel analysis in establishing a diagnosis for patients with dementia. Furthermore, give us insight into the complexity of the genetic background of this group of disorders.
- Open Access
- 1 January 2022
- Published by National Library of Serbia in Genetika
- Vol. 54 (3) , 1313-1330
C9ORF72 repeat expansion is not associated with atypical parkinsonism in the Serbian population
These include, among others, two forms of atypical Parkinsonism, multiple system atrophy (MSA) and progressive supranuclear palsy (PSP). This study aimed to assess the potential role of C9orf72 repeat expansions among Serbian patients diagnosed with MSA and PSP. Genomic DNA of 44 MSA patients, 73 PSP patients, and 96 controls was extracted from peripheral blood, and normal C9orf72 alleles were analyzed by standard quantitative fluorescence polymerase chain reaction (QF-PCR) and fragment analysis. Subsequently, for all samples presenting a single allele, repeat-primed PCR was performed with two different sets of primers to avoid a false-negative result. Thirty repeats were used as a pathogenic cut-off and 20-29 repeats for the intermediate alleles. No pathological C9orf72 expansions were detected in the MSA and PSP patients nor the control subjects. In the MSA group, the most common was the allele with 2 repeats, and the largest repeat number was 14. Among PSP patients, the most common allele also had 2 repeats, while the largest detected repeat size within the normal range was 17. Also, we identified one PSP patient that had an intermediate size allele (25 repeats). We did not find correlation between the number of repeats and disease onset, age at the time of examination, or disease duration in MSA or PSP patients. Regarding family history, in PSP the sum of both allele repeats numbers was higher in patients with positive family history than in sporadic cases. The results presented in this study are the first systematic assessment of C9orf72 allele sizes among patients diagnosed with MSA and PSP in the Serbian population. Although the potential role of intermediate C9orf72 repeats in neurodegenerative disorders is still to be elucidated, our results support the current knowledge that C9orf72 repeat expansions are not associated with MSA and PSP.
- 1 January 2022
- Published by National Library of Serbia in Genetika
- Vol. 54 (3) , 1313-1330
Open AccessC9ORF72 repeat expansion is not associated with atypical parkinsonism in the Serbian population
These include, among others, two forms of atypical Parkinsonism, multiple system atrophy (MSA) and progressive supranuclear palsy (PSP). This study aimed to assess the potential role of C9orf72 repeat expansions among Serbian patients diagnosed with MSA and PSP. Genomic DNA of 44 MSA patients, 73 PSP patients, and 96 controls was extracted from peripheral blood, and normal C9orf72 alleles were analyzed by standard quantitative fluorescence polymerase chain reaction (QF-PCR) and fragment analysis. Subsequently, for all samples presenting a single allele, repeat-primed PCR was performed with two different sets of primers to avoid a false-negative result. Thirty repeats were used as a pathogenic cut-off and 20-29 repeats for the intermediate alleles. No pathological C9orf72 expansions were detected in the MSA and PSP patients nor the control subjects. In the MSA group, the most common was the allele with 2 repeats, and the largest repeat number was 14. Among PSP patients, the most common allele also had 2 repeats, while the largest detected repeat size within the normal range was 17. Also, we identified one PSP patient that had an intermediate size allele (25 repeats). We did not find correlation between the number of repeats and disease onset, age at the time of examination, or disease duration in MSA or PSP patients. Regarding family history, in PSP the sum of both allele repeats numbers was higher in patients with positive family history than in sporadic cases. The results presented in this study are the first systematic assessment of C9orf72 allele sizes among patients diagnosed with MSA and PSP in the Serbian population. Although the potential role of intermediate C9orf72 repeats in neurodegenerative disorders is still to be elucidated, our results support the current knowledge that C9orf72 repeat expansions are not associated with MSA and PSP.